ECHDC3 and acute myeloid leukemia: By extension of our previous finding of changed ECHDC3 expression in chemoresistant AML, the current study made a comprehensive analysis with bioinformatic analysis and experimental verification, supporting ECHDC3 as a novel biomarker predicting poor-prognosis AML, which might further improve risk stratification in AML subgroups.